Platelet [3H]dopamine uptake is differentially affected by neuroleptic drug treatment in schizophrenia and schizophreniform disorder

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)

Abstract

1. The uptake of [3H]dopamine was measured using platelet-rich plasma (PRP) from neuroleptic- free subjects and again, in some cases, after the subject had been treated with neuroleptic drugs. 2. There were no differences in [3H]dopamine uptake by PRP in subjects who were or were not mentally ill. 3. After treatment with neuroleptic drugs the Km for platelet [3H]dopamine uptake had increased in 76% of subjects with schizophrenia and 87% of subjects with schizophreniform disorder. Similarly, the Vmax for platelet [3H]dopamine uptake had increased in 81% of the subjects with schizophrenia and 86% of the subjects with schizophreniform disorder. 4. By contrast, the Km for platelet [3H]dopamine uptake had decreased in 94% of subjects who had a psychoses associated with an illness other than schizophrenia or schizophreniform disorder whilst the Vmax for platelet [3H]dopamine uptake also decreased by 94% in these subjects. 5. In subjects with psychoses, platelet [3H]dopamine uptake is differentially altered during euroleptic drug treatment depending on diagnosis.

Original languageEnglish
Pages (from-to)45-55
Number of pages11
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume20
Issue number1
DOIs
Publication statusPublished - 1 Jan 1996
Externally publishedYes

Keywords

  • Dopamine
  • Neuroleptic drugs
  • Platelet
  • Schizophrenia

Cite this

@article{37ba6ff59be6482590a1937dc14b5792,
title = "Platelet [3H]dopamine uptake is differentially affected by neuroleptic drug treatment in schizophrenia and schizophreniform disorder",
abstract = "1. The uptake of [3H]dopamine was measured using platelet-rich plasma (PRP) from neuroleptic- free subjects and again, in some cases, after the subject had been treated with neuroleptic drugs. 2. There were no differences in [3H]dopamine uptake by PRP in subjects who were or were not mentally ill. 3. After treatment with neuroleptic drugs the Km for platelet [3H]dopamine uptake had increased in 76{\%} of subjects with schizophrenia and 87{\%} of subjects with schizophreniform disorder. Similarly, the Vmax for platelet [3H]dopamine uptake had increased in 81{\%} of the subjects with schizophrenia and 86{\%} of the subjects with schizophreniform disorder. 4. By contrast, the Km for platelet [3H]dopamine uptake had decreased in 94{\%} of subjects who had a psychoses associated with an illness other than schizophrenia or schizophreniform disorder whilst the Vmax for platelet [3H]dopamine uptake also decreased by 94{\%} in these subjects. 5. In subjects with psychoses, platelet [3H]dopamine uptake is differentially altered during euroleptic drug treatment depending on diagnosis.",
keywords = "Dopamine, Neuroleptic drugs, Platelet, Schizophrenia",
author = "Brian Dean and Suresh Sundram and Christine Hill and Copolov, {David L.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1016/0278-5846(95)00291-X",
language = "English",
volume = "20",
pages = "45--55",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Platelet [3H]dopamine uptake is differentially affected by neuroleptic drug treatment in schizophrenia and schizophreniform disorder

AU - Dean, Brian

AU - Sundram, Suresh

AU - Hill, Christine

AU - Copolov, David L.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - 1. The uptake of [3H]dopamine was measured using platelet-rich plasma (PRP) from neuroleptic- free subjects and again, in some cases, after the subject had been treated with neuroleptic drugs. 2. There were no differences in [3H]dopamine uptake by PRP in subjects who were or were not mentally ill. 3. After treatment with neuroleptic drugs the Km for platelet [3H]dopamine uptake had increased in 76% of subjects with schizophrenia and 87% of subjects with schizophreniform disorder. Similarly, the Vmax for platelet [3H]dopamine uptake had increased in 81% of the subjects with schizophrenia and 86% of the subjects with schizophreniform disorder. 4. By contrast, the Km for platelet [3H]dopamine uptake had decreased in 94% of subjects who had a psychoses associated with an illness other than schizophrenia or schizophreniform disorder whilst the Vmax for platelet [3H]dopamine uptake also decreased by 94% in these subjects. 5. In subjects with psychoses, platelet [3H]dopamine uptake is differentially altered during euroleptic drug treatment depending on diagnosis.

AB - 1. The uptake of [3H]dopamine was measured using platelet-rich plasma (PRP) from neuroleptic- free subjects and again, in some cases, after the subject had been treated with neuroleptic drugs. 2. There were no differences in [3H]dopamine uptake by PRP in subjects who were or were not mentally ill. 3. After treatment with neuroleptic drugs the Km for platelet [3H]dopamine uptake had increased in 76% of subjects with schizophrenia and 87% of subjects with schizophreniform disorder. Similarly, the Vmax for platelet [3H]dopamine uptake had increased in 81% of the subjects with schizophrenia and 86% of the subjects with schizophreniform disorder. 4. By contrast, the Km for platelet [3H]dopamine uptake had decreased in 94% of subjects who had a psychoses associated with an illness other than schizophrenia or schizophreniform disorder whilst the Vmax for platelet [3H]dopamine uptake also decreased by 94% in these subjects. 5. In subjects with psychoses, platelet [3H]dopamine uptake is differentially altered during euroleptic drug treatment depending on diagnosis.

KW - Dopamine

KW - Neuroleptic drugs

KW - Platelet

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0029658101&partnerID=8YFLogxK

U2 - 10.1016/0278-5846(95)00291-X

DO - 10.1016/0278-5846(95)00291-X

M3 - Article

C2 - 8861176

AN - SCOPUS:0029658101

VL - 20

SP - 45

EP - 55

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 1

ER -